Obtained drug clinical trial approval notice
April 15, 2025
Source: drugdu
80
Hengrui Medicine announced on the evening of April 13 that the company received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration for HRS-9190 for injection, and will conduct clinical trials in the near future. HRS-9190 for injection is a Class 1 new drug for intraoperative medication, used for tracheal intubation during the induction period of general anesthesia and maintaining skeletal muscle relaxation during surgery. The company announced on the same day that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration for SHR-3792 injection, and will conduct clinical trials in the near future. SHR-3792 injection is an innovative anti-tumor drug candidate independently developed by the company, which has shown good anti-tumor activity in preclinical animal models. Upon inquiry, no similar drugs have been approved for marketing at home and abroad.
https://finance.eastmoney.com/a/202504133375232889.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Chairman of Baili Tianheng donates 30 million yuan to Fudan University to support the development of innovative drug target discovery and other teacher training needs May 13, 2025
- ‘This is my most important and impactful post’ May 13, 2025
- Adverse waist-to-height ratio trajectories during childhood linked to early cardiometabolic risk May 13, 2025
- Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs May 13, 2025
- Jiudian Pharmaceuticals received the supplementary application for change of marketing authorization holder for its drug May 13, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
